Ankaferd Blood Stopper for controlling gastrointestinal bleeding due to distinct benign lesions refractory to conventional antihemorrhagic measures

Kurt, Mevlut; Onal, Ibrahim; Akdogan, Meral; KEKİLLİ, MURAT; Arhan, Mehmet; Sayilir, Abdurrahim; Oztas, Erkin; HAZNEDAROĞLU, İBRAHİM

doi:10.1155/2010/896819

Ankaferd Blood Stopper for controlling gastrointestinal bleeding due to distinct benign lesions refractory to conventional antihemorrhagic measures

Copy For Citation

Kurt M., Onal I. K., Akdogan M., KEKİLLİ M., Arhan M., Sayilir A., ...More

CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol.24, no.6, pp.380-384, 2010 (SCI-Expanded)

Publication Type: Article / Article
Volume: 24 Issue: 6
Publication Date: 2010
Doi Number: 10.1155/2010/896819
Journal Name: CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.380-384
Keywords: Ankaferd Blood Stopper, Bleeding, Dieulafoy's lesion, Mallory-Weiss tear, Polypectomy, Radiation colitis, MALLORY-WEISS-SYNDROME, ANTRAL VASCULAR ECTASIA, COMPLICATION, EFFICACY, ULCER, MODEL
Gazi University Affiliated: No

Abstract

OBJECTIVE: To assess the hemostatic efficacy of the Ankaferd Blood Stopper (ABS, Ankaferd Health Products Ltd, Turkey) hemostatic agent for controlling gastrointestinal bleeding associated with various benign lesions refractory to conventional antihemorrhagic measures.